查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1775587

單株抗體市場：2025年至2030年的預測

Monoclonal Antibodies Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

單株抗體市場預計將從 2025 年的 2,014.29 億美元成長到 2030 年的 3,407 億美元，複合年成長率為 11.08%。

免疫系統會自然產生抗體來應付感染疾病。單株抗體是指旨在增強人體自然免疫系統對入侵者（如癌症和感染疾病）反應的分子。由於單株抗體是在實驗室中開發的，因此它們被歸類為人造藥物。單株抗體優於其他類型的感染疾病治療方法，因為它們是特異性設計用於針對感染過程的重要部分。它們是透過將白血球暴露於特定的病毒蛋白質所產生的。然後對它們進行克隆以大量生產針對該病毒的抗體。單株抗體已被開發用於治療多種病毒感染疾病，包括伊波拉出血熱和狂犬病。單株抗體已開發用於治療多種病毒感染疾病，包括伊波拉出血熱和狂犬病，在臨床試驗證明其可有效減輕疾病嚴重程度後，在 COVID-19 大流行期間被廣泛使用。

推動單株抗體市場成長的因素：

  • 單株抗體的需求不斷增加

根據世界衛生組織 (WHO) 的數據，2020 年全球約有 1,000 萬人死於癌症。單株抗體在癌症治療中非常有效，這使得對價格合理的抗癌藥物的需求日益成長。此外，在新冠疫情期間，許多單株抗體臨床試驗旨在開發新的藥物療法，並獲得了廣泛的產品核可，可用於緊急治療新冠疫情。

市場也正在不斷發展以滿足對單株抗體醫藥品日益成長的需求，這些藥物旨在為複雜和嚴重的疾病提供高度特異性的治療，進一步刺激單株抗體市場的成長潛力。

單株抗體市場的地理展望：

  • 預計北美將在預測期內佔據主要市場佔有率

北美國家擁有發達的醫療保健基礎設施，但該地區的大量飲酒和垃圾速食文化導致肥胖，使人們患癌症的風險更高。

此外，新的疫苗和藥物正在研發中，以幫助治療癌症患者。 Amneal Pharmaceuticals宣佈在美國推出Bevacizumab（Alymsys）。該藥物是Bevacizumab（Avastin，基因泰克）的生物相似藥。Bevacizumab由mAbxience開發。它可用於治療轉移性大腸直腸癌、第一線非鱗狀非小細胞肺癌、持續性、復發性和轉移性子宮頸癌以及上皮性卵巢癌、輸卵管癌和原發性腹膜癌。

目錄

第1章 引言

  • 市場概覽
  • 市場定義
  • 市場區隔

第2章調查方法

  • 調查數據
  • 先決條件

第3章執行摘要

  • 調查重點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 業內競爭對手之間的競爭
  • 產業價值鏈分析

5. 單株抗體市場（依適應症分類），2020 年至 2030 年

  • 介紹
  • 發炎性疾病
  • 癌症
  • 微生物疾病
  • 其他

6. 單株抗體市場（依來源分類），2020 年至 2030 年

  • 介紹
  • 人性化
  • 人類
  • 嵌合體
  • 老鼠

7. 單株抗體市場（按應用分類），2020 年至 2030 年

  • 介紹
  • 診斷
  • 治療
  • 其他

8. 單株抗體市場（依最終用戶分類），2020 年至 2030 年

  • 介紹
  • 醫院和診所
  • 實驗室

9. 單株抗體市場（按地區分類），2020 年至 2030 年

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 印度
    • 泰國
    • 台灣
    • 其他

第10章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第11章 公司簡介

  • Eli Lilly and Company
  • AbbVie, Inc.
  • Novartis AG
  • Bristol Myers Squibb
  • F.Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • Merck & Co. Inc.
  • AstraZeneca PLC
簡介目錄
Product Code: KSI061610595

The Monoclonal Antibodies Market is expected to grow from US$201.429 billion in 2025 to US$340.700 billion in 2030, at a CAGR of 11.08%.

The immune system naturally produces antibodies in response to an infection. A monoclonal antibody is a molecule designed to enhance the body's natural immune system response against an invader, such as cancer or an infection. It is developed in a laboratory and hence comes under man-made drugs. Monoclonal antibodies are created to specifically target an essential part of the infectious process, and therefore, they have an advantage over other types of treatment for infections. It is created by exposing a white blood cell to a particular viral protein. It is then cloned to mass-produce antibodies, which target that virus. The monoclonal antibodies are developed to treat several viral infections, such as Ebola and rabies. They were widely used during the COVID-19 pandemic, as the clinical trials proved that the antibodies are effective in reducing the severity.

Monoclonal Antibodies Market Growth Drivers:

  • Increased demand for monoclonal antibodies

According to the World Health Organization, around 10 million people died due to cancer worldwide in 2020. For cancer treatment, monoclonal antibodies are significantly helpful, therefore, there is an increasing need for affordable cancer therapies. Moreover, during the COVID-19 pandemic, many monoclonal antibodies' clinical trials took place in order to develop novel drug therapy, as well as a wide range of product approvals were made for emergency use in COVID-19 treatment.

With its growing demand, the market players have a strong focus on the development as well as the discovery of monoclonal antibody therapeutics. The step has been taken to offer highly specific treatment for complex and severe diseases. Furthermore, it will stimulate the monoclonal antibodies market growth potential.

Monoclonal Antibodies Market Geographical Outlook:

  • North America is expected to hold a significant market share during the anticipated period

North American countries have a well-developed healthcare infrastructure. However, the high intake of alcohol and junk/fast food culture in this region is leading to obesity and putting the population at a high risk of being infected with cancer.

Furthermore, new vaccines/drugs are being developed to help in the treatment of cancer patients. Amneal Pharmaceuticals announced the launch of bevacizumab-maly (Alymsys) in the United States. The drug is a biosimilar reference of bevacizumab (Avastin, Genentech). Bevacizumab-maly is developed by mAbxience. The drug will be useful in the treatment of metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Monoclonal Antibodies Market Segmentation:

By Indication

  • Inflammatory Disease
  • Cancer
  • Microbial Disease
  • Others

By Source

  • Humanized
  • Human
  • Chimeric
  • Murine

By Application

  • Diagnostic
  • Therapeutic
  • Others

By End-User

  • Hospitals & Clinics
  • Research Laboratories

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. MONOCLONAL ANTIBODIES MARKET, BY INDICATION (2020-2030)

  • 5.1. Introduction
  • 5.2. Inflammatory Disease
  • 5.3. Cancer
  • 5.4. Microbial Disease
  • 5.5. Others

6. MONOCLONAL ANTIBODIES MARKET, BY SOURCE (2020-2030)

  • 6.1. Introduction
  • 6.2. Humanized
  • 6.3. Human
  • 6.4. Chimeric
  • 6.5. Murine

7. MONOCLONAL ANTIBODIES MARKET, BY APPLICATION (2020-2030)

  • 7.1. Introduction
  • 7.2. Diagnostic
  • 7.3. Therapeutic
  • 7.4. Others

8. MONOCLONAL ANTIBODIES MARKET, BY END-USER (2020-2030)

  • 8.1. Introduction
  • 8.2. Hospitals & Clinic
  • 8.3. Research Laboratories

9. MONOCLONAL ANTIBODIES MARKET, BY GEOGRAPHY (2020-2030)

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. Japan
    • 9.6.3. South Korea
    • 9.6.4. India
    • 9.6.5. Thailand
    • 9.6.6. Taiwan
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. Eli Lilly and Company
  • 11.2. AbbVie, Inc.
  • 11.3. Novartis AG
  • 11.4. Bristol Myers Squibb
  • 11.5. F.Hoffmann-La Roche Ltd.
  • 11.6. Johnson & Johnson Services, Inc.
  • 11.7. Amgen Inc.
  • 11.8. Merck & Co. Inc.
  • 11.9. AstraZeneca PLC